Burden of chronic obstructive pulmonary disease: Healthcare costs and beyond

Allergy and Asthma Proceedings

Volumn 36, Issue 1, 2015, Pages 4-10

  May, Sara M ^a   Li, James T C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; LONG ACTING DRUG;

ANTIBIOTIC THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PROTOCOL; COMORBIDITY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION COST; HUMAN; MAINTENANCE THERAPY; MORBIDITY; MORTALITY; OUTPATIENT CARE; PREVALENCE; QUALITY OF LIFE; RISK FACTOR; SMOKING; COST OF ILLNESS; DISEASE COURSE; HOSPITALIZATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

COST OF ILLNESS; DISEASE PROGRESSION; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MORBIDITY; MORTALITY; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 84919725444     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2015.36.3812     Document Type: Article

References (71)

1. World Health Organization. The global burden of disease: 2004 update. 2008. Available at www.who.int/healthinfo/global-burden-disease/GBD-report-2004update-full.pdf. Accessed June 11, 2014.
2. Chronic Obstructive Pulmonary Disease (COPD). Available at http://www.cdc.gov/copd/data.htm. Accessed June 11, 2014.
3. Michalski JM. Prostaglandin E2 signaling in human lung fibroblasts: mechanisms of signal attenuation and implications in chronic lung diseases. ProQuest, UMI Dissertation Publishing, 2011.
4. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med 186:975-981, 2012.
5. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187:347-365, 2013.
6. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176:532-555, 2007.
7. Calverley PM, and Walker P. Chronic obstructive pulmonary disease. Lancet 362:1053-1061, 2003.
8. World Helath Organization. Global status report on noncommunicable diseases 2010. Geneva, 2011. Available at http://www.who.int/nmh/publications/ncd-report2010/en/. Accessed June 23, 2014.
9. National Heart, Lung and Blood Institute. Morbidity and Mortality: 2012 chartbook on Cardiovascular, lung, and blood diseases. 2012. Available at http://www.nhlbi.nih.gov/resources/docs/2012-ChartBook-508.pdf. Accessed June 23, 2014.
10. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. MMWR Surveill Summ 51:1-16, 2002.
11. Eisner MD, Anthonisen N, Coultas D, et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 182:693-718, 2010.
12. Centers for Disease Control and Prevention. Chronic obstructive pulmonary disease among adults - United States, 2011. 2012. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6146a2.htm. Accessed June 11, 2014.
13. Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 28:523-532, 2006.
14. Soriano JB, Maier WC, Egger P, et al. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 55:789-794, 2000.
15. Sørheim IC, Johannessen A, Gulsvik A, et al. Gender differences in COPD: are women more susceptible to smoking effects than men? Thorax 65:480-485, 2010.
16. Buist AS, McBurnie MA, Vollmer WM, et al., BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 370:741-750, 2007.
17. Rennard SI, and Farmer SG. COPD in 2001: a major challenge for medicine, the pharmaceutical industry, and society. Chest 121:113S-115S, 2002.
18. Rennard S, Decramer M, Calverley PM, et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 20:799-805, 2002.
19. Ferguson GT, and Petty TL. Screening and early intervention for COPD. Hosp Pract 1998;33:67-72, 9-80, 3; discussion 3-4, 1995.
20. Zieliñski J, Bednarek M, and Know the Age of Your Lung Study Group. Early detection of COPD in a high-risk population using spirometric screening. Chest 119:731-736, 2001.
21. National Cancer Institute. Changes in number of cigarettes smoked per day: cross-sectional and birth cohort analyses using NHIS. 2003. Available at http://cancercontrol.cancer.gov/brp/tcrb/monographs/15/monograph15-chapter7.pdf. Accessed June 23, 2014.
22. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med 368:351-364, 2013.
23. Pleis JR, Lucas JW, and Ward BW. Summary health statistics for U.S. adults: National Health Interview Survey, 2008. Vital Health Stat 10:1-157, 2009.
24. Economic Facts About U.S. Tobacco Production and Use. 2014. Available at http://www.cdc.gov/tobacco/data-statistics/fact-sheets/economics/econ-facts/. Accessed August 20, 2014.
25. Fletcher C, and Peto R. The natural history of chronic airflow obstruction. Br Med J 1:1645-1648, 1977.
26. Rennard SI, and Vestbo J. Natural histories of chronic obstructive pulmonary disease. Proc Am Thorac Soc 5:878-883, 2008.
27. Hill K, Goldstein RS, Guyatt GH, et al. Prevalence and under-diagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ 182:673-678, 2010.
28. Holt PG. Immune and inflammatory function in cigarette smokers. Thorax 42:241-249, 1987.
29. Tager IB, Ngo L, and Hanrahan JP. Maternal smoking during pregnancy. Effects on lung function during the first 18 months of life. Am J Respir Crit Care Med 152:977-983, 1995.
30. Hnizdo E, Sullivan PA, Bang KM, and Wagner G. Airflow obstruction attributable to work in industry and occupation among U.S. race/ethnic groups: a study of NHANES III data. Am J Ind Med 46:126-135, 2004.
31. Matheson MC, Benke G, Raven J, et al. Biological dust exposure in the workplace is a risk factor for chronic obstructive pulmonary disease. Thorax 60:645-651, 2005.
32. Trupin L, Earnest G, San Pedro M, et al. The occupational burden of chronic obstructive pulmonary disease. Eur Respir J 22:462-469, 2003.
33. Torres-Duque C, Maldonado D, Pérez-Padilla R, et al., Forum of International Respiratory Studies (FIRS) Task Force on Health Effects of Biomass Exposure. Biomass fuels and respiratory diseases: a review of the evidence. Proc Am Thorac Soc 5:577-590, 2008.
34. Orozco-Levi M, Garcia-Aymerich J, Villar J, et al. Wood smoke exposure and risk of chronic obstructive pulmonary disease. Eur Respir J 27:542-546, 2006.
35. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:1418-1422, 1998.
36. Gore JM, Brophy CJ, and Greenstone MA. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax 55:1000-1006, 2000.
37. Celli BR, Halbert RJ, Nordyke RJ, and Schau B. Airway obstruction in never smokers: results from the Third National Health and Nutrition Examination Survey. Am J Med 118:1364-1372, 2005.
38. Lamprecht B, McBurnie MA, Vollmer WM, et al. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest 139:752-763, 2011.
39. FitzGerald JM, Haddon JM, Bradly-Kennedy C, et al., RUSIC Study Group. Resource use study in COPD (RUSIC): a prospective study to quantify the effects of COPD exacerbations on health care resource use among COPD patients. Can Respir J 14:145-152, 2007.
40. Maleki-Yazdi MR, Kelly SM, Lam SY, et al. The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada. Can Respir J 19:319-324, 2012.
41. Yeatts KB, Lippmann SJ, Waller AE, et al. Population-based burden of COPD-related visits in the ED: return ED visits, hospital admissions, and comorbidity risks. Chest 144:784-793, 2013.
42. Yohannes AM, Willgoss TG, Baldwin RC, and Connolly MJ. Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease: prevalence, relevance, clinical implications and management principles. Int J Geriatr Psychiatry 25:1209-1221, 2010.
43. Aghanwa HS, and Erhabor GE. Specific psychiatric morbidity among patients with chronic obstructive pulmonary disease in a Nigerian general hospital. J Psychosom Res 50:179-183, 2001.
44. Vögele C, and von Leupoldt A. Mental disorders in chronic obstructive pulmonary disease (COPD). Respir Med 102:764-773, 2008.
45. Willgoss TG, Yohannes AM, Goldbart J, and Fatoye F. "Everything was spiraling out of control": experiences of anxiety in people with chronic obstructive pulmonary disease. Heart Lung 41:562-571, 2012.
46. Tálamo C, de Oca MM, Halbert R, et al. Diagnostic labeling of COPD in five Latin American cities. Chest 131:60-67, 2007.
47. Peña VS, Miravitlles M, Gabriel R, et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBER-POC multicentre epidemiological study. Chest 118:981-989, 2000.
48. Kochanek KD XJ, Murphy SL, Miniño AM, and Kung H. Deaths: final data for 2009. Natl Vital Stat Rep 60:1-116, 2011.
49. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 121:121S-126S, 2002.
50. Chan-Yeung M, Aït-Khaled N, White N, et al. The burden and impact of COPD in Asia and Africa. Int J Tuberc Lung Dis 8:2-14, 2004.
51. Gonzalez-Pier E, Gutierrez-Delgado C, Stevens G, et al. [Priority setting for health interventions in Mexico's System of Social Protection in Health]. Salud Publica Mex 49(Suppl. 1):S37-S52, 2007.
52. Jamison DT. Investing in Health. In Disease Control Priorities in Developing Countries. Jamison DT, Breman JG, Measham AR, et al. (Eds) 2nd ed. Washington, DC, 2006.
53. Kessler R, Ståhl E, Vogelmeier C, et al. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest 130:133-142, 2006.
54. Spencer S, Calverley PM, Burge PS, and Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 23:698-702, 2004.
55. Donaldson GC, Seemungal TA, Bhowmik A, and Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57: 847-852, 2002.
56. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60:925-931, 2005.
57. Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161:1608-1613, 2000.
58. Kanner RE, Anthonisen NR, and Connett JE. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med 164:358-364, 2001.
59. Dalal AA, Shah M, D'Souza AO, and Rane P. Costs of COPD exacerbations in the emergency department and inpatient setting. Respir Med 105:454-460, 2011.
60. Aaron SD, Vandemheen KL, Hebert P, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 348:2618-2625, 2003.
61. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106:196-204, 1987.
62. Davies L, Angus RM, and Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 354:456-460, 1999.
63. Wood-Baker RR, Gibson PG, Hannay M, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005:CD001288.
64. Quon BS, Gan WQ, and Sin DD. Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis. Chest 133:756-766, 2008.
65. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006:CD004403.
66. Akazawa M, Halpern R, Riedel AA, et al. Economic burden prior to COPD diagnosis: a matched case-control study in the United States. Respir Med 102:1744-1752, 2008.
67. Bustacchini S, Chiatti C, Furneri G, et al. The economic burden of chronic obstructive pulmonary disease in the elderly: results from a systematic review of the literature. Curr Opin Pulm Med 17(Suppl. 1):S35-S41, 2011.
68. Ford ES, Murphy LB, Khavjou O, et al. Total and state-specific medical and absenteeism costs of chronic obstructive pulmonary disease among adults aged a 18 years in the United States for 2010 and projections through 2020. Chest 2014. doi: 10.1378/chest.14-0972. [Epub ahead of print]
69. National Institute of Health. Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC). 2014. Available at http://report.nih.gov/categorical-spending.aspx. Accessed June 30, 2014.
70. Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, and Rutten-van Molken MP. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health 8:178-190, 2005.
71. Nickels AS, Joshi AY, and Dinakar C. Electronic cigarettes: navigating the vapor. Ann Allergy Asthma Im 112:481-483, 2014.